

Corona Remedies commences capacity expansion for commercial production at Bhayla facility in Gujarat

29 December 2025 | News

The installed capacity of the facility will increase by 400 million



Corona Remedies has announced the successful commencement of capacity expansion for commercial production of tablets and capsules at its Bhayla manufacturing facility, effective from December 22, 2025.

This strategic expansion aims to meet the growing market demand and enhance the company's in-house production capabilities. With this addition, the installed capacity of the facility will increase by 400 million, raising the available capacity by 240 million.

This milestone reinforces the company's commitment to optimising production and streamlining its supply chain. The expansion is fully funded through internal accruals and is expected to improve operational efficiency and ensure a more agile supply chain.

As of March 31, 2025, the Bhayla facility has an installed capacity of 852.80 million units, with an impressive capacity utilization rate of 93.58%. This development marks a significant step in Corona Remedies' growth trajectory and is aligned with its long-term vision of scaling operations to cater to increasing market demands.

Corona manufactures products for healthcare solutions as per international quality standards in its WHO-GMP/EU GMP-certified plant. The company has 2 DSIR-approved R&D centres with 80+ scientist teams working on new formulation

development.